Clinical Trial Search

Primary: Complete Response Rate (Cohort 1) — 0 percentage of participants

Primary: Overall Objective Response Rate, Defined as the Proportion of Patients Who Have a Minor Response (MR), Partial Response (PR), or Complete Response(CR)Assessed According…

Primary: Progression-Free Survival (PFS) — 10.0; 5.7 months — p=0.080

Primary: Progression Free Survival — 241 days

Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001

Primary: Increased Radioiodine Uptake — 6 Participants

Primary: Objective Response Rate (ORR) — 50.0; 35.6 Percentage of participants

Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg

Primary: Overall Response (OR) — 0; 3; 3; 1 Participants

Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants

Primary: Median Progression Free Survival — 12.5 months

Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants

Primary: Objective Response Rate — 6 Participants

Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants

Primary: Tumor Response Rate to LBH589. — 13; 0 participants

Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change

Primary: Number of Participants With Overall Response (OR) — 0 Participants

Primary: Time to Tumor Progression — 334; 176 days

Primary: Change in Tumor Size — 4.7 cm

Primary: Overall Survival Rate — 0 percentage of participants alive

Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…

Primary: Objective Response Rate (ORR) as of Week 24 (ORR24wk) — 57.3; 40.3 percentage of participants

Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants

Primary: Changes in Thyroid Nodule Size — 0.241361; 0.954909; 0.422121; 0.104143 mL

Primary: Overall Response Rate — 11 Participants

Primary: Maximum Tolerated Dose (MTD) of Cisplatin (Phase I) — 100 mg/m^2

Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants

Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants